CARLSBAD, California, June 2, 2011 /PRNewswire/ --
- Further analysis on Ion PGM(TM) will confirm data with goal to develop accurate testing kits to screen samples
Life Technologies Corporation today announced that preliminary data from DNA sequencing performed in cooperation with the University Hospital Muenster, Germany, on the Ion Personal Genome Machine (PGM(TM)) strongly suggests that the bacterium at the root of the deadly outbreak in Germany is a new hybrid type of pathogenic E. coli strains.
The data obtained from the DNA sequencer shows the presence of genes typically found in two different types of E. coli: enteroaggregative E. coli (EAEC) and enterohemorrhagic E. coli (EHEC). These results, which are being confirmed by further data analysis on the Ion PGM(TM), may provide insight into this bacterium's aggressiveness and help prevent further outbreaks.
"The rapid whole genome sequencing results enabled us to discover within days a unique combination of virulence traits ... and makes this German outbreak clone a unique hybrid of different E. coli pathovars," said Dr. med. Alexander Mellmann, scientist at the German National Consulting Laboratory for Hemolytic Uremic Syndrome (HUS) at the Institute of Hygiene, University Hospital Muenster.
The data gathered at Life Technologies' laboratories in Darmstadt, Germany, will be used by scientists at the University Hospital Muenster, to develop better tests to positively identify the illness in people showing symptoms of the infection, which includes kidney failure and bloody diarrhea. For the first time since the outbreak, it is now possible to study in detail the basis for what makes this strain so aggressive.
Life Technologies' Simone Guenther, Ph.D., who carried out the sequencing work, said: "The severity of this outbreak meant that speed was of the essence. We were able to provide the data in record time to University Hospital Muenster. In previous outbreaks it would have taken much longer to reach this stage."
To prevent further spreading of the bacterium, Life Technologies began shipping its custom E. coli testing kits to European laboratories this week to screen contaminated food thought to be at the center of the outbreak that has killed 17 people and affected more than 1,000 in Europe.
The kits serve as a first line of defense to detect the presence of pathogenic E. coli. Secondary testing is then performed using more specific kits. Life Technologies will develop new customized kits specifically designed to detect the hybrid strain in Germany once the sequencing data has been fully analyzed in the next few days. The company can design custom assays in less than one week.
The kits shipped to Europe are part of a large offering of molecular tests developed by Life Technologies capable of accurately detecting most pathogens that are dangerous to humans. The Ion PGM(TM) is a DNA sequencing instrument featuring semiconductor technology that can complete a highly accurate sequence of DNA in just two hours. The DNA sample used for the sequencing work was collected from a patient with the illness.
The Ion Personal Genome Machine sequencer is for research use only. Not for use in diagnostic procedures.
About Life Technologies (http://www.lifetechnologies.com)
Life Technologies Corporation is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and TaqMan(R) products. Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Contact Mauricio Minotta +1-760-929-2456 Mauricio.firstname.lastname@example.org
SOURCE Life Technologies Corporation